Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEBRO study of eplerenone-based versus irbesartan-based blood pressure lowering in obese hypertensive adults
2018-004809-58Phase 3Active
- Sponsor
- International Institute for the Study, Research, Education and Therapy of Vascular, Heart, Brain and Stroke Disorders
- Start
- Feb 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of eplerenone and irbesartan in essential hypertension and obesity (2 arms), sponsored by International Institute for the Study, Research, Education and Therapy of Vascular, Heart, Brain and Stroke Disorders. Primary endpoint: Reduction in 24-hour ambulatory blood pressure at 24 weeks. Started Feb 2019; status: active.
02
Drugs
eplerenoneirbesartan
03
Conditions
essential hypertensionobesity
Beyond the preview
Go deeper on 2018-004809-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004809-58.